CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells

• 来源期刊: 细胞研究（英文版）
• 年，卷（期）: 2017,（1）
• 页码范围: 154-157
• 页数: 4页
• 语种: 中文
• DOI: 10.1038/cr.2016.142

摘要

Dear Editor, Chimeric antigen receptor (CAR) T cell therapy is a promising approach to treat cancer,such as B-cell malignancy [1].However,the current standard treatment requires autologous adoptive cell transfer,which is expensive and time-consuming.For newborn and elder patients,it is often difficult to obtain enough T cells with good quality to generate patient-specific CAR-T cells.